ORMP Overview

Rights Agreement Adoption: Oramed Pharmaceuticals has adopted a Rights Agreement to protect stockholders in the event of a hostile takeover, allowing them to purchase shares at a set price if certain ownership thresholds are met.

Details of the Rights: Each Right allows stockholders to buy one share of Common Stock at $10.00, becoming exercisable if a person or group acquires 15% or more of the company's stock, with specific terms for redemption and exchange.

Dividend Distribution: A dividend of one Right will be distributed for each outstanding share of Common Stock, payable on November 27, 2025, to stockholders of record as of that date.

Forward-Looking Statements: The press release includes forward-looking statements regarding the Rights Plan and its potential effects, emphasizing that actual results may differ due to various uncertainties.

Strong Financial Performance: Oramed Pharmaceuticals reported a net income of $65 million for the nine months ending September 30, 2025, a significant turnaround from a net loss of $6.1 million in the same period last year.

Asset Growth: The company's total assets increased by 42% year-over-year, rising from $155.3 million to $220.5 million, reflecting robust balance sheet growth.

Investment Returns: The financial improvement was largely driven by cash returns from Scilex Holding Company and unrealized gains from investments in Alpha Tau Medical Ltd. and others.

Management Insights: CEO Nadav Kidron emphasized the effectiveness of their disciplined investment strategy, which has enhanced financial flexibility and supports ongoing development of their oral drug delivery platform.

Oral Insulin Program Update: Oramed Pharmaceuticals is advancing its oral insulin program independently, launching a new U.S. trial to validate its formulation based on promising results from identified high-responder subgroups.

Investment Portfolio Performance: The company has strategically invested in various biomedical firms, achieving significant returns, including a $99.5 million loan to Scilex and investments in Alpha Tau and BioXcel, which have shown substantial gains.

Shareholder Commitment: Oramed reaffirms its commitment to rewarding shareholders, including plans for a one-time dividend, despite the termination of a joint venture that would have facilitated this.

Growth Strategy and Financial Health: The company reports a growth in total cash and assets to approximately $210 million, highlighting its ability to create value through strategic capital deployment and a diversified investment approach.

Strategic Investment Announcement: Oramed Pharmaceuticals has made a strategic investment in Alpha Tau Medical, purchasing approximately 14.1 million shares to support the development of Alpha Tau's innovative cancer therapy technology, Alpha DaRT.

Collaboration Goals: The partnership aims to leverage Oramed's expertise in capital markets and business strategy to accelerate Alpha Tau's clinical trials, manufacturing expansion, and commercialization efforts, while also enhancing governance through board appointments.